Literature DB >> 6302230

The response of the (myelinating) Schwann cell population to multiple episodes of demyelination.

S M Hall.   

Abstract

The effects of multiple intraneural injections of the known demyelinating agent lysophosphatidyl choline, LPC, have been studied in the sciatic nerves of adult mice. Up to six separate episodes of demyelination were induced at the same site within the tibial fascicle. Demyelination and subsequent remyelination occurred after each injection. The number of Schwann cells produced during each repair programme exceeded the number required for remyelination and some of the surplus cells temporarily remained associated with the remyelinating axon/Schwann cell units as supernumerary Schwann cells. There was a progressive decline in the proportion of promyelinated axons as the number of injections of LPC increased. The proposition that this could have reflected a more rapid repair following demyelination of thinly (re)myelinated axons was investigated in double LPC-injected nerves. No structures resembling onion bulbs characteristic of hypertrophic neuropathies in man were seen during the course of this study.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302230     DOI: 10.1007/bf01148084

Source DB:  PubMed          Journal:  J Neurocytol        ISSN: 0300-4864


  2 in total

1.  Human immunodeficiency virus (HIV)-related chronic relapsing inflammatory demyelinating polyneuropathy with multifocal unusual onion bulbs in sural nerve biopsy. A clinicomorphological study with qualitative and quantitative light and electron microscopy.

Authors:  E Gibbels; N Diederich
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

2.  Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.

Authors:  Lin Ma; Hitoshi Uchida; Jun Nagai; Makoto Inoue; Jerold Chun; Junken Aoki; Hiroshi Ueda
Journal:  Mol Pain       Date:  2009-11-13       Impact factor: 3.395

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.